# A Study to Evaluate the Safety, Tolerability, and Activity of Intravenous MLDL1278A in Patients on Standard-of-Care Therapy for Stable Atherosclerotic Cardiovascular Disease (GLACIER)

Study · id `cardio:ct-nct01258907` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01258907](<https://clinicaltrials.gov/study/NCT01258907>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT01258907

Browse, organ or system: Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 147 participants.

## Technical summary

Registry record NCT01258907. Randomized; double masking; primary purpose treatment. Start 2010-03 (registry gives no type); primary completion 2012-07 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 147 participants (enrolled count; ClinicalTrials.gov record NCT01258907, source copy `cardio:ctgov-nct01258907-2016-11-02`, retrieved 2026-10-31)
- Start date: 2010-03 (registry gives no type) (ClinicalTrials.gov record NCT01258907, source copy `cardio:ctgov-nct01258907-2016-11-02`, retrieved 2026-10-31)
- Primary completion: 2012-07 (actual) (ClinicalTrials.gov record NCT01258907, source copy `cardio:ctgov-nct01258907-2016-11-02`, retrieved 2026-10-31)
- Completion: Not reported
- Countries: United States; Canada (ClinicalTrials.gov record NCT01258907, source copy `cardio:ctgov-nct01258907-2016-11-02`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01258907-2016-11-02`, retrieved 2026-10-31)

## The registry's words

- Brief title: A Study to Evaluate the Safety, Tolerability, and Activity of Intravenous MLDL1278A in Patients on Standard-of-Care Therapy for Stable Atherosclerotic Cardiovascular Disease (GLACIER)
- Condition: Atherosclerosis
- Intervention (Drug): MLDL1278A
- Intervention (Drug): MLDL1278A
- Intervention (Drug): placebo
- Intervention (Drug): statin, stable dose
- Lead sponsor: Genentech, Inc.
- Lead sponsor class: INDUSTRY
- Collaborator: BioInvent International AB
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Atherosclerosis (`cardio:atherosclerosis`)
- Registry lists this organization as the lead sponsor: Genentech, Inc. (`cardio:org-genentech-inc`)

## Provenance

Content hash: fc405eed8d5ee683cb52677a8150916de1b78e11175ee0e9916e96583f1c3487
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
